Wells Fargo Maintains Overweight on Immunovant, Raises Price Target to $47
Benzinga Newsdesk 6 hours ago
Analyst RatingsNewsPrice Target
Wells Fargo analyst Derek Archila maintains Immunovant (NASDAQ:IMVT) with a Overweight and raises the price target from $45 to $47.
Wells Fargo analyst Derek Archila maintains Immunovant (NASDAQ:IMVT) with a Overweight and raises the price target from $45 to $47.